$APOP and Quoin Pharmaceuticals Announce Strategic Merger

Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger

Cellect shareholders to retain 25% of the combined Company pre-funding

Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor.

Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank.

Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.